Dr. Mark C. Liu

Dr. Danoff is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and Co-Director of the Hopkins Interstitial Lung Disease Clinic. She is a specialist in diseases causing fibrosis or scarring in the lung, particularly those associated with autoimmune diseases including myositis. Dr. Danoff is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Lung Transplant, and Endoscopy. Dr. Danoff is board certified in American Board Of Internal Medicine.

Schar Chair, Advanced Lung Disease and Lung Transplant Medical Director, Advanced Lung Disease and Lung Transplant Program, Inova Schar Heart and Vascular Professor of Medical Education, University of Virginia, Inova CampusSteven D. Nathan, MD, FCCP, is the medical director of Inova’s Advanced Lung Disease Program and Lung Transplant Program. He is also a professor of medicine at the University of Virginia.Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. The author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including U.S. Food and Drug Administration advisory boards as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he has also served as chair. Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences. Dr. Nathan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Prostatectomy.

Paul M. Hassoun, M.D., is professor of medicine at the Johns Hopkins University School of Medicine and the director of the pulmonary hypertension program at Johns Hopkins Hospital. He received his medical degree from the Faculté de Médecine Lariboisière-Saint Louis at the University of Paris, France, completed an internship and residency at Brigham and Women’s Hospital and a fellowship in Pulmonary and Critical Care Medicine at Massachusetts General Hospital, both at Harvard Medical School. He was on faculty in the pulmonary division at New England Medical Center/Tufts University School of Medicine (Tufts-NEMC) in Boston, MA, until 2002 when he joined the division of pulmonary and critical care medicine at Johns Hopkins University. Dr. Hassoun has served or currently serves on numerous American Thoracic Society (ATS) assemblies and committees, including the Pulmonary Circulation Long Range Planning Committee, the Pulmonary Circulation Program Committee (for which he served as chair for 2008-2009), the ATS Scientific Advisory Council, Pulmonary Circulation Leadership Committee, and the American College of Chest Physicians Vascular Steering Committee. He served as the ATS Pulmonary Circulation chair (2011-2012) and on the ATS Publications Policy Committee. He was recently elected president of the Pulmonary Vascular Research Institute (PVRI; 2018-2019). Dr. Hassoun has held numerous editorial activities including serving on the editorial board of the American Journal of Respiratory and Critical Medicine (2010 to present), CHEST (2006-2015) and the European Respiratory Review (2008-2015). He currently serves as associate editor of the European Respiratory Journal (2013-present) and has served as associate editor for the Journal of Clinical Investigation (2017-2022). Dr. Hassoun is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Systemic Sclerosis (SSc), Cerebral Hypoxia, Pulmonary Veno-Occlusive Disease, and Lung Transplant. Dr. Hassoun is board certified in American Board Of Internal Medicine.